Tumor Necrosis Factor Receptor Superfamily Member 9 / CD137 (TNFRSF9) Antibody

182€ (25 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Tumor Necrosis Factor Receptor Superfamily Member 9 / CD137 (TNFRSF9) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx414444
tested applications
ELISA, FCM
Description
Tumor Necrosis Factor Receptor Superfamily Member 9 (CD137) Antibody is a Rat Monoclonal antibody against Tumor Necrosis Factor Receptor Superfamily Member 9 (CD137).
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Tumor Necrosis Factor Receptor Superfamily Member 9 / CD137 (TNFRSF9) |
| Host | Rat |
| Reactivity | Human |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG2a |
| Purification | Purified |
| Size 1 | 25 µg |
| Form | Liquid |
| Tested Applications | ELISA, FCM |
| Buffer | PBS. Contains sodium azide. |
| Availability | Shipped within 3-7 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q07011 |
| Alias | Tumor necrosis factor receptor superfamily member 9,ILA,4-1BB,CD137,CDw137,IMD109,4-1BB ligand receptor,T-cell antigen 4-1BB homolog,T-cell antigen ILA |
| Background | Antibody anti-TNFRSF9 |
| Status | RUO |
| Note | Concentration: 1.0 mg/ml - |
Descripción
TNFRSF9, also known as 4-1BB or CD137, is a member of the tumor necrosis factor receptor (TNFR) superfamily and plays a key role in immune regulation. This receptor is expressed primarily on activated T cells, as well as on natural killer (NK) cells, dendritic cells, and some other immune cell types, particularly after stimulation. It serves as a co-stimulatory receptor, enhancing T-cell proliferation, survival, and effector function, making it pivotal in immune responses and antitumor immunity. TNFRSF9 has gained attention as a therapeutic target in cancer immunotherapy due to its role in enhancing immune cell activation and persistence. Upon binding with its ligand, TNFSF9 (also known as 4-1BB ligand or 4-1BBL), TNFRSF9 undergoes trimerization, which is essential for transmitting downstream signaling. This receptor’s functions extend beyond tumor immunity; it is also involved in chronic inflammation and autoimmune diseases, and as such, modulation of TNFRSF9 signaling has therapeutic implications across several pathologies.
Related Products

Human TNFRSF9/4-1BB (Tumor necrosis factor receptor superfamily member 9) ELISA Kit
Ver Producto
Human TNFRSF9/4-1BB (Tumor necrosis factor receptor superfamily member 9) ELISA Kit
Ver Producto